AR092104A1 - LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) - Google Patents

LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)

Info

Publication number
AR092104A1
AR092104A1 ARP130102859A ARP130102859A AR092104A1 AR 092104 A1 AR092104 A1 AR 092104A1 AR P130102859 A ARP130102859 A AR P130102859A AR P130102859 A ARP130102859 A AR P130102859A AR 092104 A1 AR092104 A1 AR 092104A1
Authority
AR
Argentina
Prior art keywords
laquinimod
gaba
treatment
disorders mediated
aminobutiric acid
Prior art date
Application number
ARP130102859A
Other languages
English (en)
Inventor
Martino Gianvito
Centonze Diego
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR092104A1 publication Critical patent/AR092104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Método para tratar un sujeto que padece un trastorno relacionado con el GABA, que comprende administrarle periódicamente al sujeto una cantidad eficaz para efectuar el tratamiento de laquinimod o de una sal farmacéuticamente aceptable de éste. Reivindicación 31: Una composición farmacéutica que comprende una cantidad de laquinimod, caracterizada porque es eficaz para tratar un sujeto humano que padece un trastorno relacionado con el GABA.
ARP130102859A 2012-08-13 2013-08-12 LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA) AR092104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261682576P 2012-08-13 2012-08-13

Publications (1)

Publication Number Publication Date
AR092104A1 true AR092104A1 (es) 2015-03-25

Family

ID=50066660

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102859A AR092104A1 (es) 2012-08-13 2013-08-12 LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)

Country Status (8)

Country Link
US (1) US9161936B2 (es)
EP (1) EP2882438A4 (es)
AR (1) AR092104A1 (es)
CA (1) CA2881973A1 (es)
IL (1) IL237042A0 (es)
MX (1) MX2015001888A (es)
TW (1) TW201410244A (es)
WO (1) WO2014028397A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
AU2013341506A1 (en) 2012-11-07 2015-06-04 Teva Pharmaceutical Industries Ltd. Amine salts of Laquinimod
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060276393A1 (en) * 2005-01-13 2006-12-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
JP5832716B2 (ja) 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
KR20160013273A (ko) 2006-06-12 2016-02-03 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP1886996A1 (en) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
EP2097065A2 (en) * 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
AU2007338771A1 (en) 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
KR20110048571A (ko) 2008-09-03 2011-05-11 테바 파마슈티컬 인더스트리즈 리미티드 면역 기능을 지닌 ２―옥소―１,２―다이하이드로―퀴놀린 조절제
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP3028572A1 (en) 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
EA025468B1 (ru) 2009-07-30 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение болезни крона с применением лаквинимода
PL3064206T3 (pl) * 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
CA2791691A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
JP2013521305A (ja) 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いるループス関節炎の治療
CA2791709A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
SG186948A1 (en) 2010-07-09 2013-02-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
US20120010239A1 (en) 2010-07-09 2012-01-12 Ulf Tomas Fristedt 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
CA2817290A1 (en) 2010-11-11 2012-05-18 Josef Penninger Compounds and methods for treating pain
SG10201509831XA (en) 2010-12-07 2015-12-30 Teva Pharma Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
IN2014MN00333A (es) 2011-07-28 2015-09-25 Teva Pharma
JP2014521659A (ja) 2011-07-28 2014-08-28 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
AR090885A1 (es) 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
UY34896A (es) 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
TW201410243A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2961406A4 (en) 2012-10-12 2017-01-04 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
AU2013341506A1 (en) 2012-11-07 2015-06-04 Teva Pharmaceutical Industries Ltd. Amine salts of Laquinimod
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
JP2016513665A (ja) 2013-03-14 2016-05-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドの経皮製剤

Also Published As

Publication number Publication date
TW201410244A (zh) 2014-03-16
WO2014028397A2 (en) 2014-02-20
US9161936B2 (en) 2015-10-20
IL237042A0 (en) 2015-03-31
US20140045886A1 (en) 2014-02-13
EP2882438A2 (en) 2015-06-17
EP2882438A4 (en) 2016-08-03
WO2014028397A3 (en) 2015-07-16
MX2015001888A (es) 2015-05-07
CA2881973A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
BR112015022197A2 (pt) tratamento de cataplexia
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015006341A2 (pt) compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
CO6630082A2 (es) Tratamiento de lupus nefritis usando laquinimod
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
MX2014002492A (es) Sal de colina de un compuesto anti - inflamatorio de ciclobutenodiona sustituida.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
AR092104A1 (es) LAQUINIMOD EN EL TRATAMIENTO DE LOS TRASTORNOS MEDIADOS POR EL ACIDO g-AMINOBUTIRICO (GABA)
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
EA201490495A1 (ru) Новые легкоразрушающиеся ингибиторы rock
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс

Legal Events

Date Code Title Description
FB Suspension of granting procedure